



ÅRSREGNSKAPET FOR REGNSKAPSÅRET 2021 - GENERELL INFORMASJON

Enheten

Organisasjonsnummer:	914 158 877
Organisasjonsform:	Aksjeselskap
Foretaksnavn:	VIATRIS AS
Forretningsadresse:	Hagaløkkveien 26 1383 ASKER

Regnskapsår

Årsregnskapets periode:	01.01.2021 - 31.12.2021
-------------------------	-------------------------

Konsern

Morselskap i konsern:	Ja
Konsernregnskap lagt ved:	Nei

Regnskapsregler

Regler for små foretak benyttet:	Nei
Benyttet ved utarbeidelsen av årsregnskapet til selskapet:	Regnskapslovens alminnelige regler

Årsregnskapet fastsatt av kompetent organ

Bekreftet av representant for selskapet:	Deloitte AS
Dato for fastsettelse av årsregnskapet:	27.06.2022

Grunnlag for avgivelse

År 2021: Årsregnskapet er elektronisk innlevert
År 2020: Tall er hentet fra elektronisk innlevert årsregnskap fra 2021

Det er ikke krav til at årsregnskapet m.v. som sendes til Regnskapsregisteret er undertegnet. Kontrollen på at dette er utført ligger hos revisor/enhetens øverste organ. Sikkerheten ivaretas ved at innsender har rolle/rettighet for innsending av årsregnskapet via Altinn, og ved at det bekreftes at årsregnskapet er fastsatt av kompetent organ.

Brønnøysundregistrene, 06.07.2023



Resultatregnskap

Beløp i: NOK	Note	2021	2020
RESULTATREGNSKAP			
Inntekter			
Revenue		557 131 888	579 985 949
Sum inntekter	10	557 131 888	579 985 949
Kostnader			
Raw materials and consumables used		455 344 205	472 916 402
Employee benefits expense	7	41 802 363	40 987 572
Amortization and depreciation	2	24 038 382	24 038 382
Other expenses	8, 13	32 975 731	40 265 001
Sum kostnader		554 160 682	578 207 357
Driftsresultat		2 971 207	1 778 591
Finansinntekter og finanskostnader			
Annen renteinntekt		-42 330	
Other financial income		126 448	196 067
Sum finansinntekter		84 118	196 067
Rentekostnad til foretak i samme konsern		2 339 419	2 995 714
Annen rentekostnad		4 610	71 756
Other financial expenses		176 438	178 130
Sum finanskostnader		2 520 466	3 245 601
Netto finans		-2 436 349	-3 049 534
Ordinært resultat før skattekostnad		534 858	-1 270 943
Income tax expense	6, 14	4 830 639	4 555 917
Ordinært resultat etter skattekostnad		-4 295 781	-5 826 860
Årsresultat		-4 295 781	-5 826 860
Årsresultat etter minoritetsinteresser		-4 295 781	-5 826 860
Totalresultat		-4 295 781	-5 826 860



Resultatregnskap

Beløp i: NOK	Note	2021	2020
Overføringer og disponeringer			
Konsernbidrag		-742 804	546 141
Transferred from other equity	1, 4	-3 552 977	-6 373 001
Sum overføringer og disponeringer		-4 295 781	-5 826 860



Balanse

Beløp i: NOK	Note	2021	2020
BALANSE - EIENDELER			
Anleggsmidler			
Immaterielle eiendeler			
Intangibles	2	13 000 000	15 000 000
Utsatt skattefordel	6, 14	2 662 561	2 509 463
Goodwill	2	149 796 998	171 718 510
Sum immaterielle eiendeler		165 459 559	189 227 973
Varige driftsmidler			
Equipment and other movables	2	211 024	327 894
Sum varige driftsmidler		211 024	327 894
Finansielle anleggsmidler			
Investering i datterselskap		120 000	120 000
Lån til foretak i samme konsern	9		
Sum finansielle anleggsmidler		120 000	120 000
Sum anleggsmidler		165 790 584	189 675 868
Omløpsmidler			
Varer			
Sum varer	11	549 200	792 930
Fordringer			
Accounts receivables		87 596 320	87 524 072
Other short-term receivables	12	986 393	532 114
Krav på innbetaling av selskapskapital	9	5 676 467	22 134 041
Sum fordringer		94 259 180	110 190 227
Bankinnskudd, kontanter og lignende			
Cash and cash equivalents	3	27 462 943	26 452 503
Sum bankinnskudd, kontanter og lignende		27 462 943	26 452 503
Sum omløpsmidler		122 271 323	137 435 660
SUM EIENDELER		288 061 907	327 111 527



Balanse

Beløp i: NOK	Note	2021	2020
BALANSE - EGENKAPITAL OG GJELD			
Egenkapital			
Innskutt egenkapital			
Share capital	1, 4	1 500 000	1 500 000
Overkurs			1 726 024
Annen innskutt egenkapital		20 654 999	
Sum innskutt egenkapital		22 154 999	3 226 024
Sum egenkapital	1, 4	22 154 999	3 226 024
Gjeld			
Langsiktig gjeld			
Pensjonsforpliktelser	5	9 049 487	7 664 390
Utsatt skatt	6, 14		
Sum avsetninger for forpliktelser		9 049 487	7 664 390
Annen langsiktig gjeld			
Other non-current liabilities	9	142 107 999	195 220 890
Sum annen langsiktig gjeld		142 107 999	195 220 890
Sum langsiktig gjeld		151 157 486	202 885 280
Kortsiktig gjeld			
Short term group liabilities	9	58 330 945	71 538 802
Leverandørgjeld		4 676 882	3 714 753
Tax payable	6, 14	4 132 027	4 252 840
Public taxes due		26 204 532	25 077 942
Other current liabilities		21 405 034	16 415 887
Sum kortsiktig gjeld		114 749 421	121 000 223
Sum gjeld		265 906 908	323 885 503
SUM EGENKAPITAL OG GJELD		288 061 907	327 111 527



Annual Accounts 2021

Viatriis AS

a Viatriis company

Contents

Annual report
Income statement
Balance sheet
Notes
Cash flow analysis



VIATRIS



Annual report 2021

Viatriis AS

The type and location of the business

Viatriis AS is a company operating within the trade of pharmaceuticals, over the counter drugs and medical devices. The company is located in Asker municipality.

Viatriis AS was up until November 2020 part of the global pharmaceutical company, Mylan. In the fall of 2019, it was announced that Mylan would merge with UpJohn, Pfizer's division of established products, forming a completely new company - Viatriis Inc. The merger took place on the 16th of November 2020, and Viatriis AS is now a Viatriis company.

With a commercial reach of 165+ countries, a global workforce of 45 000+ employees and a portfolio of 1400+ molecules – VIATRIS™ is a new kind of healthcare company, committed to providing access to medicines, advancing sustainable operations, developing innovative solutions, and leveraging our collective expertise to improve patient outcomes. Formed in 2020 through the combination of Mylan and Upjohn, Viatriis brings together best-in-class scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver quality medicines to patients when and where they need them.

Products and future development

The company has grown significantly in recent years due to acquisitions of both products and companies. Viatriis AS now has broad product portfolio within both prescription and over-the-counter medicines and products, and medical equipment. Both original products and generic drugs are marketed. The products are sold to end customers via retail pharmacies and hospital pharmacies, either through agreements with the individual pharmacy chain or public tenders.

In 2021, the following were, measured by revenue, the largest products:

- Inluvac - a vaccine against seasonal flu. Mylan won 40% of the national tender for the four-valent seasonal flu vaccine; this applies to risk groups that should be vaccinated annually. The agreement has a duration of 2 years and initially applies to the seasons 2019/2020 and 2020/2021. There is also an option attached to the agreement with an extension for another 1 + 1 years. In 2021 – 700 380 doses of Inluvac were delivered to The Norwegian Institute of Public Health.
- Dymista - a nasal spray with azelastine hydrochloride and fluticasone propionate for the treatment of allergic rhinitis. Dymista has been a focus product for the sales force since its launch almost 7 years ago and has had strong growth. The product has continued to grow through 2021 and at the end of the year had a market share in value of more than 60%.



- TrioBe - a prescription vitamin B and folic acid tablet. The product has for many years been one of the largest products in the Meda portfolio and has continued to sell well through 2021. Competing products have entered the market from other suppliers, but the competition from these has not been as strong as expected.
- Divisun - a prescription vitamin D preparation for the treatment of vitamin D deficiency. Divisun has like Dymista, been one of the focus areas for the sales force for several years. In recent years, the product has faced greater competition from over-the-counter competitors in some of the strengths. In 2021, close to 173 000 packs of Divisun were sold.
- EpiPen - an epinephrine autoinjector and a medical device for injecting a measured dose or doses of epinephrine by means of autoinjector technology. It is most often used for the treatment of anaphylaxis. More than 93 500 doses sold in 2021.

Working environment, equal opportunity, and discrimination

The board considers that the working environment in the company is good. No special measures have been implemented in this connection. The employees of the business have not suffered any accidents or injury in connection with their work. Total sick leave over the last year has been 34 days, which amounts to 0,4% of total working time in the fiscal year. This is stable over the past years.

A goal for Viatris AS is to be a workplace where there is full equality of opportunity between men and women. The company has established a personnel policy that is considered gender neutral in all areas. At the end of year, the company had 38 employees, 23 women and 15 men. The company's board consists of 3 persons, of whom none are women.

Environmental reporting

The company operates from modern and environmentally friendly facilities in Asker Tek, Asker. It does not carry out activity that pollutes the external environment.

Corporate social responsibility and sustainability

Corporate social responsibility is fundamental to the VIATRIS™ mission. We work to advance response and sustainable operations and leverage our collective expertise to empower people to live healthier at every stage of life, recognizing that our actions affect the stakeholders and communities we serve.

A partner for sustainable development:

Viatris supports the UN Global Compact and the global sustainable development agenda for 2030, as articulated by the United Nations in the adoption of the Sustainable Development Goals (SDGs) in 2015. For these goals to be achieved, companies must play a purposeful and active role.



Our mission and business model directly contribute to SDG 3: Good Health and Well-Being, among others. Health and well-being are also affected by many of the challenges we face today, such as antimicrobial resistance, climate change and other environmental concerns, demographic changes, and growing inequity, as well as government financial constraints. Viatris is committed to doing its part to help address these complex problems. We also believe that in taking on these challenges, we can create value for our stakeholders and help build a more sustainable future for all.

As the journey of Viatris continues, we will work hard to leverage our unique capabilities, address inherent risks and be a reliable partner today and into the future.

Going concern

In accordance with § 3-3a of the Accounting Act it is confirmed that the going concern assumption is satisfied and this assumption has been applied in the preparation of the accounts. Due to decline in equity, the company received a shareholder contribution of 25 million from parent company Meda AB in 2021.

Report on the annual accounts

The board is not aware of any matters that are important for an assessment of the company's position and result that are not set out in the annual accounts. Similarly, no matters have occurred after the end of the financial year that in the opinion of the board are material to an assessment of the accounts.

The operating revenues in the company decreased from 580,0 million in 2020 to 557,1 million in 2021. Main reason, causing approximate 20 million of the reduction in revenue is the divestment of products as a result of the Viatris integration with UpJohn in November 2020.

The ordinary result before tax expense is positive with 0,5 million for 2021, compared to negative 1,3 million in 2020

Operating expenses are lower than last year, in majority driven by the decrease in cost of goods. There are slight increases in personnel cost, mainly driven by payroll and correlating cost like payroll taxes and pension plan cost. Other operating expenses are down by 7,3 million, this is largely driven by full year effect of intercompany recharges related to the UpJohn integration. There is also reduction in intercompany recharges to the company as well as regulatory fees.

The company's liquidity at fiscal yearend was at 27,5 million compared to 26,5 million the year before.

Total assets at the end of year were 288,1 million, compared to 327,1 million the preceding year.

The equity ratio has changed from 1,0% in 2020 to 7,7 % in 2021. As per the section on going concern, the company received an unconditional shareholder contribution of 25 million from parent company Meda AB in 2021.

At the end of the financial year, current liabilities accounted for 43,2% of total debt (37,4% the year before). Long-term debt of 142,1 million is related to the acquisition of Meda AS in 2018.



The company operates with limited financial risk. All transactions with the parent company are in Norwegian kroner and there are a small number of transactions and balance sheet figures that are in foreign currency. The company has no loans or securities that expose the company to interest rate risk.

Liability insurance for general manager and members of the board

Viatrix AS has set up liability insurance for the general manager and board of directors.

Annual result and allocations

The 2021 annual result of after tax is negative with NOK 4 295 781 and will in its entirety covered by a transfer from other equity

Application	Amount
Received group contribution	-1 244 454
Accrued group contribution (after tax)	501 650
Transferred from other equity	-3 552 977
Total application and allocation	-4 295 781

Asker, 27.06.2022

The board of Viatrix AS

Luis
Birbuet

Digitally signed by Luis Birbuet
DN: cn=Luis Birbuet, o=Viatrix,
ou=Viatrix Northern & Western
Head, email=luis.birbuet@viatrix.com,
c=ES
Date: 2022.06.27 14:00:20 +02'00'

Luis Birbuet
Chairman of the board

Jan Ulrik
Stevnsborg-
g-
m317141

Digitalt signeret
af Jan Ulrik
Stevnsborg-
m317141
Dato: 2022.06.29
09:03:44 +02'00'

Jan Ulrik Stevnsborg
Country Manager/
Member of the board

Kurt Glud-
M528452

Digitally signed by
Kurt Glud-
M528452
Date: 2022.06.29
08:54:16 +02'00'

Kurt Glud
Member of the board



Viatrix AS

INCOME STATEMENT 01.01. - 31.12.

	Note	2021	2020
Revenue		557 131 888	579 985 949
Total operating income	10	557 131 888	579 985 949
Raw materials and consumables used		455 344 205	472 916 402
Employee benefits expense	7	41 802 363	40 987 572
Amortization and depreciation	2	24 038 382	24 038 382
Other expenses	8, 13	32 975 731	40 265 001
Total operating expenses		554 160 682	578 207 357
Operating profit		2 971 207	1 778 591
Other interest income		-42 330	0
Other financial income		126 448	196 067
Interest expense to group companies		-2 339 419	-2 995 714
Other interest expenses		-4 610	-71 756
Other financial expenses		-176 438	-178 130
Ordinary result before taxes		534 858	-1 270 943
Income tax expense	6, 14	4 830 639	4 555 917
Net profit after tax		-4 295 781	-5 826 860
Annual result		-4 295 781	-5 826 860
Application and allocation			
Received group contribution		-1 244 454	0
Accrued group contribution (after tax)		501 650	546 141
Transferred from other equity	1, 4	-3 552 977	-6 373 001
Total application and allocation		-4 295 781	-5 826 860



BALANCE SHEET PER 31.12.

	Note	2021	2020
ASSETS			
Intangibles	2	13 000 000	15 000 000
Deferred tax assets	6, 14	2 662 561	2 509 463
Goodwill	2	149 796 998	171 718 510
Total intangible assets		165 459 559	189 227 973
Property, plant and equipment			
Equipment and other movables	2	211 024	327 894
Total property, plant and equipment		211 024	327 894
Non-current financial assets			
Investments in subsidiaries		120 000	120 000
Total non-current financial assets		120 000	120 000
Total non-current assets		165 790 584	189 675 868
Current assets			
Inventories	11	549 200	792 930
Debtors			
Accounts receivables		87 596 320	87 524 072
Other short-term receivables	12	986 393	532 114
Receivables on group companies	9	5 676 467	22 134 041
Total receivables		94 259 180	110 190 227
Investments			
Cash and cash equivalents	3	27 462 943	26 452 503
Total current assets		122 271 323	137 435 660
TOTAL ASSETS		288 061 907	327 111 527



BALANCE SHEET PER 31.12.

	Note	2021	2020
EQUITY AND LIABILITIES			
EQUITY			
Paid-in capital			
Share capital	1, 4	1 500 000	1 500 000
Share premium reserve		0	1 726 024
Other paid-up equity		20 654 999	0
Total paid-up equity		22 154 999	3 226 024
Retained earnings			
Total equity	1, 4	22 154 999	3 226 024
LIABILITIES			
Provisions			
Employee benefit obligations	5	9 049 487	7 664 390
Total provisions		9 049 487	7 664 390
Other non-current liabilities			
Other non-current liabilities	9	142 107 999	195 220 890
Total non-current liabilities		142 107 999	195 220 890
Current liabilities			
Short term group liabilities	9	58 330 945	71 538 802
Trade payables		4 676 882	3 714 753
Tax payable	6, 14	4 132 027	4 252 840
Public taxes due		26 204 532	25 077 942
Other current liabilities		21 405 034	16 415 887
Total current liabilities		114 749 421	121 000 223
Total liabilities		265 906 908	323 885 503
TOTAL EQUITY AND LIABILITY		288 061 907	327 111 527

Asker, 27.06.2022
The board of Viatris AS

Luis
Birbuet

Luis Birbuet
Chairman of the board

Digitally signed by Luis Birbuet
DN: cn=Luis Birbuet, ou=Viatri,
ou=Viatri Northern & Western
Head,
email=luis.birbuet@viatris.com,
c=ES
Date: 2022.06.27 14:00:26 +0200'

Jan Ulrik
Stevnsborg
g-
m317141

Jan Ulrik Stevnsborg
Country Manager

Digitalt signeret
af Jan Ulrik
Stevnsborg-
m317141
Dato: 2022.06.29
09:03:44 +02'00'

Kurt Glud-
M528452

Kurt Glud
Member of the board

Digitally signed by
Kurt Glud-
M528452
Date: 2022.06.29
08:54:40 +02'00'



Notes to the annual accounts 2021
Viatris AS

Accounting policies

The financial statements have been prepared in accordance with Norwegian Accounting Act and generally accepted accounting principles in Norway.

Revenue recognition

Revenue from the sale of manufactured goods and goods for resale is recognised in the Income Statement when delivery is made and risk has passed to the buyer. Revenue from services provided is recognised as they are delivered.

Classification and assessment of balance sheet items

Assets intended for long term ownership or use have been classified as fixed assets. Assets expected to be realized in, or is intended for sale or consumption in, the entity's normal operating cycle have been classified as current assets. Receivables are classified as current assets if they are expected to be realized within twelve months after the transaction date. Similar criteria apply to liabilities.

Current assets are valued at the lower of cost and fair value. Short term liabilities are reflected at normal value.

Fixed assets are carried at historical cost. Fixed assets whose value will deteriorate are depreciated on a straight line basis over the asset's estimated useful life. Fixed assets are written down to net realizable value if a value reduction occurs which is not expected to be temporary. Except for accruals, long term liabilities started in Norske Kroner are reflected in the balance sheet at nominal value on the establishment date. Accruals are discounted to present value if the time value of money is material.

Intangible assets

Intangible assets are recognized in the balance sheet providing that probable future economic benefits associated with development of the intangible assets can be identified and the costs can be measured reliably. Otherwise, the costs are expensed as incurred. Intangible assets recognized in the balance sheet are amortized on a straight-line basis over their useful economic life.

Fixed assets

Fixed assets are recognized in the balance sheet and depreciated over the estimated useful economic life, given the asset has life expectancy of more than 3 years and a cost price exceeding NOK 15 000. Maintenance costs are expensed as incurred as other operating expenses, whereas improvements and additions are added to the acquisition cost and depreciated with the assets. The distinction between maintenance and improvements is made with regard to the asset's relative condition at the original purchase date.

Trade and other receivables

Trade and other receivables are recognized in the balance sheet at nominal value after deduction of provision for bad debts. The provision for bad debts is estimated on the basis of an individual assessment of each major receivable. We do not expect any loss due to bad debts.

Inventories

Inventories are stated at the lower of cost and net realizable value. Provision on inventory is calculated on estimated obsolescence.

Foreign currencies

Items denominated in foreign currencies are translated into local currency at the exchange rate on the balance sheet date.

Tax

The tax expense in the income statement consists both of taxes payable for the accounting period, and the period's changes in deferred tax. Deferred tax assets is calculated with 22% of the temporary differences between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Temporary differences, both positive and negative, are offset within the same period. Deferred tax assets is recorded in the balance sheet when it is more likely than the tax assets will be utilized. Deferred tax assets and deferred tax liabilities are presented net in the balance sheet.



Notes to the annual accounts 2021
Viatrix AS

Pensions

Mylan Healthcare Norge AS is obliged to keep an occupational pension scheme in accordance with the Norwegian Mandatory Occupational Pensions Act, and has taken out such a pension scheme for all employees.

Pension costs and pension obligations are calculated on a straight-line basis based on assumptions about the discount rate, future adjustment of salaries, pensions and benefits from the National Insurance Scheme, future returns on pension funds and actuarial assumptions about mortality, voluntary retirement, etc. Pension funds are valued at fair value in the balance sheet. When accounting for pensions, the linear accrual profile and expected final salary are used as the basis for accrual. Plan changes are expensed when incurred.

In estimating pension assets and pension liabilities, the estimated value at the closing of the accounts has been used. The estimated values are corrected each year in accordance with calculations made by the actuary and booked directly in equity.

Cash flow analysis

The cash flow statement is prepared according to the indirect method. Cash and cash equivalents include cash, bank deposits and other short-term, liquid investments that can be immediately and with insignificant exchange rate risk converted into known cash amounts and with a remaining term of less than three months from the date of acquisition.

Note 1 Equity

Changes in equity this year	Share capital	Premium	Other paid-up equity	Retained earnings	Total
Equity 1.1.	1 500 000	1 726 024		-	3 226 024
Pension postings - actuarial loss	-	-	(2 518 048)	-	(2 518 048)
Profit/ loss for the year	-	(1 726 024)	(2 569 757)	-	(4 295 781)
Received shareholder contribution			25 000 000	-	25 000 000
Given group contribution Zpearpoint	-	-	(501 650)	-	(501 650)
Received group contribution Zpearpoint			1 244 454		1 244 454
Equity 31.12.	1 500 000	-	19 410 545	-	22 154 999

The company has received an unconditional shareholder contribution of 25 million from parent company Meda AB in 2021.

Note 2 Intangible assets, goodwill and tangible assets

	Tangible assets	Intangible assets	Goodwill	Total intangible assets, tangible assets and goodwill
Acquisition cost 1.1.	662 279	20 000 000	219 215 120	239 877 399
Additions	-	-	-	-
Disposals	-	-	-	-
Acquisition cost 31.12.	662 279	20 000 000	219 215 120	239 877 399
Accumulated depreciation 31.12.	451 255	7 000 000	69 418 122	76 869 377
Balanseført verdi pr. 31.12.	211 024	13 000 000	149 796 998	163 008 022

This year's depreciation
in %

116 870	2 000 000	21 921 512	24 038 382
15.8 %	10.0 %	10.0 %	9.3 %

Intangible assets are related to the acquisition of the Norwegian generics business of sister affiliate Mylan AB, Sweden; purchased on 01.07.2018. The amount will be depreciated on a straight-line basis over 10 years.

Goodwill is related to the merger of Meda AS via Startfase 942 AS in 2019, and is amortized on a straight-line basis over 10 years; this based on estimate of the life span of the product portfolio involved.

The company resides leased facilities in Asker Tek in Hagaløkkveien in Asker. Annual cost of leasing in 2021 was MNOK 1.5



Notes to the annual accounts 2021
Viatris AS

Note 3 Bank deposits and restricted funds

The company keeps its primary bank connection with Danske Bank. The bank provides guarantees related to lease of the facilities in Hagaløkkveien and withheld payroll tax.

Note 4 Share capital and shareholders

The share capital of NOK 1 500 000 consists of 30 shares with a face value of NOK 50 000 each. All shares have equal rights.

Shareholders

Meda AB 30 shares 100% ownership

No shares are owned by Managing Director or Members of the Board.

Note 5 Pension liabilities

The company has two defined benefit pension plans that cover a total of 12 working employees and 11 pensioners. These are two separate schemes based on BGP Products AS and Meda AS, respectively. In connection with the merger of the Norwegian Mylan companies, employees from Meda AS were transferred to Mylan Healthcare Norge AS effective 1 February 2019. The defined benefit plans are closed and employees hired after 01.02.2015 (BGP) and 01.01, respectively, 2012 (Meda), are part of one defined contribution pension scheme.

Defined benefit plans provide the right to defined future benefits. These are mainly dependent on the number of years of service, the salary level at retirement age and the size of the benefits from the National Insurance Scheme.

	31.12.2021	31.12.2020
Changes in actuarial gain/loss booked to equity		
Actuarial (gain)/loss 01.01.	-	-
Actuarial (gain)/loss booked to equity	3 228 267	3 376 809
Actuarial (gain)/loss 31.12.	3 228 267	3 376 809
Liabilities		
Current value on defined benefit obligations	(43 049 487)	(38 964 391)
Real value of pension funds	34 000 000	31 300 000
Liability in the balance sheet	(9 049 486)	(7 664 390)
Net	(9 049 486)	(7 664 390)
Change in plan assets		
Fair value of plan assets at beginning of year	31 300 000	31 330 000
Expected return on plan assets	865 846	1 217 087
Actuarial (gain)/loss	(1 304 616)	(3 227 426)
Cost	-	-
Benefits paid from plan assets	(267 070)	(267 070)
Employer contributions to plan	3 405 840	2 247 409
	34 000 000	31 300 001
Change in benefit obligation		
Benefit obligation at beginning of year	(38 964 391)	(36 039 857)
Service cost	(1 773 038)	(2 145 042)
Interest cost	(655 478)	(819 271)
Benefits paid from plan assets	267 070	267 070
Actuarial (gain)/loss	(1 923 651)	(227 291)
Cost	-	-



Notes to the annual accounts 2021
Viatis AS

	(43 049 488)	(38 964 391)	
Netto	(9 049 487)	(7 664 390)	
Net periodic benefit cost recognized in the income statement	2021	2020	
Service cost	1 773 037	2 145 042	
Interest cost	655 478	819 271	
Expected return on plan assets	(865 846)	(1 217 087)	
Amortization or settlement recognition of net gain (loss)	44 412	77 908	
Net pension cost	1 607 081	1 825 134	
Distributed as per	2021	2020	
Operating costs	1 773 037	2 145 042	
Financial (income)/ expense	(165 956)	(319 908)	
Total pension cost	1 607 081	1 825 134	
Actuarial assumptions to determine benefit obligations	31.12.2021	31.12.2020	
Discount rate	1.90 %	1.70 %	
Merit	2.50 %	2.00 %	
G-regulation	2.50 %	2.00 %	
Regulation of current pension - BGP plan	2.50 %	0.00 %	
Regulation of current pension - Meda plan	0.00 %	2.00 %	
Note 6 Income tax	2021	2020	
Tax payable	4 132 027	5 015 811	
Change in deferred tax asset	(153 098)	(459 895)	
Tax effect of temporary differences direct against equity	-	-	
Tax effect of group contributions	141 491	-	
Tax effect def ben pens	710 219	-	
Total tax expense	4 830 639	4 555 916	
Basis for income tax			
Profit/ (loss) before income tax	534 858	(1 270 943)	
Permanent differences	22 031 524	19 211 777	
Changes in temporary differences	695 898	2 090 432	
Given group contribution	(643 141)	(700 179)	
Defined benefit pensions	(3 228 267)	-	
Basis for tax payable liability	19 390 872	19 331 087	
22% tax payable from the basis (22% in 2020)	4 265 992	4 252 839	
Excess tax paid 2020	(133 965)	-	
Tax payable	4 132 027	4 252 839	
Temporary differences	2021	2020	Endringer
Goodwill	(2 963 212)	(3 642 286)	(679 074)
Accrual for obligations	-	-	-
Defined benefit pensions	(9 049 487)	(7 664 390)	1 385 097
Provision on inventory	(89 851)	(99 975)	(10 124)
Carry-forward deficit	-	-	-
Total	(12 102 550)	(11 406 652)	695 898
22 % carry-forward (tax benefit)/tax liability (22%-2020)	(2 662 561)	(2 509 463)	153 098



Notes to the annual accounts 2021
Viatrix AS

Note 7 Employee benefit expenses, remuneration to board and executives

	2021	2020
Wages and salaries	34 243 730	29 903 044
Payroll tax	5 677 309	4 657 815
Pension expense	3 665 122	3 496 001
Severance contracts etc.	875 536	-
Other benefits	3 636 263	3 324 164
Recharge of employee cost to other group entities	(6 295 597)	(393 451)
Total	41 802 363	40 987 572

Pension costs are divided between the defined benefit plan of NOK 1 607 081 and the defined contribution plan of NOK 2 058 041; a total of NOK 3 665 122

Bonus paid out constitutes NOK 4 180 867 of the total salary costs.

The number of employees was 37 at the beginning of the year and 38 by year end. Average number of employees during 2021 was 36.63 (36 in 2020).

Remuneration to senior executives (only country manager):

	2021	2020
Wages and salaries	-	0
Other benefits	-	0
Pension cost (incl. social tax)	-	0

The country manager is employed by the Danish sister affiliate Mylan Denmark ApS and does not receive any benefits from the company. No loans have been granted or collateral provided for the benefit of the country manager, the chairman of the board or other executives.

Note 8 Audit fees

Deloitte AS is auditor for Mylan Healthcare Norge AS. A total of NOK 399 500 has been paid to the company in fees for 2021. This constitutes of NOK 328 000 for statutory audits, NOK 16 500 for certification services and NOK 55 000 for advice and assistance on tax matters. All amounts are exclusive of VAT.

Note 9 Receivables and debts to group companies

Short term	Receivables		Debt	
	2021	2020	2021	2020
Mylan Luxembourg 2 S. à r.l	-	-	-	-
GR/IR	-	-	-	-
BGP Products Operations GmbH (Basel)	-	-	29 377 129	9 856 334
Generics UK Limited	-	-	3 296	7 854
Mylan Inc	-	-	13 441	-
Mylan B.V.	1 510 874	741 732	-	-
Mylan AB	-	-	-	-
Mylan Ireland Ltd	-	-	559 496	6 135 817
Mylan Finland OY	-	-	-	-
Mylan Hospital AS	-	-	-	1 967 000
Meda AS	624 960	15 624 960	784 660	855 449
BGP Products S. à r.l, Luxembourg	-	5 201 908	-	5 232 136
Meda AB	-	-	27 015 822	47 243 461
Ipex AB	-	-	-	-
Upjohn Export B.V.	2 296 179	565 441	-	-
Viatrix SA	-	-	47	-



Notes to the annual accounts 2021
Viatri AS

Viatri Healthcare SAS	-	-	282 926	240 752
Zpearpoint AS	-	-		
Total	4 432 013	22 134 041	58 036 817	71 538 802

Long term	Receivables		Debt	
	2021	2020	2021	2020
Mylan Luxembourg 2 S. à r.l	-	-	142 107 999	195 220 890
Total	-	-	142 107 999	195 220 890

Total from/to group companies	4 432 013	22 134 041	200 144 816	266 759 692
--------------------------------------	------------------	-------------------	--------------------	--------------------

Note 10 Revenue per business area

	2021	2020
Branded	342 476 772	327 542 972
OTC	93 064 756	87 609 946
Generics	110 085 320	152 590 541
Medical Devices	11 505 171	12 242 490
Total	557 131 888	579 985 949

All sale of goods are to customers in the Norwegian market.

There is a change in accounting principles related to joint marketing cost which as of 2021 is included as a reduction of sales and not as part of other expenses. For 2020 this cost was a total of MNOK 10.8 and 2020 numbers have been accordingly in this report.

Note 11 Inventory

	2021	2020
Finished goods	639 051	892 905
Provision on inventory	(89 851)	(99 975)
Total	549 200	792 930

Note 12 Other receivables

	2021	2020
Prepayments	986 393	532 114
Total	986 393	532 114

Note 13 Related parties transactions

	2021	2020
Purchase of goods		
Purchase of goods - sister affiliates	446 135 372	430 155 212
Purchase of services		
Purchase of administrative services - sister affiliates	3 493 797	9 488 860
Royalty Mylan Hospital	2 553 750	3 352 500
License Fee Meda AS	3 389 948	2 650 938
Total	455 572 867	445 647 510

Note 14 Events after closing date



Notes to the annual accounts 2021
Viartis AS

As part of the Viartis integration, the UpJohn portfolio was implemented to the business as of April 2022. This will for the coming years contribute to increased revenue.

Note 15 Consolidated accounts and group companies

Mylan Healthcare Norge AS is included in the consolidated accounts that are reported for ultimate parent company in the group; Viartis Inc. and these can be found via www.viartis.com/financial-and-filings/

Mylan Healthcare Norge AS is the sole shareholder of the daughter company Meda AS (org.920218199). The shares were acquired in the consolidation process for the Norwegian Mylan entities in 2018. There are no consolidated accounts prepared for the companies as this is not of significance in the evaluation of the groups position and result. This in line with the Accounting Act (Regnskapsloven) §3-8, 2 section and the Norwegian Accounting Standards (Norsk Regnskapsstandard) 17 item 5.

Subsidiary	Location	Book value	Ownership	Equity	Profit
Meda AS	Asker	120 000	100 %	1 461 931	502 214



Cash flow analysis 2021

Indirect model - numbers in thousands		
Viatris AS		
Cash flow from operations	2021	2020
Earnings before income taxes	535	-1 271
Income taxes paid	-4 253	-3 863
Amortization and depreciation	24 038	24 038
Change in pensions	-1 843	-500
Endring i varelager	244	582
Change in inventory	-72	11 264
Change in accounts receivables	962	-743
Change in accounts payables	5 661	33 563
Net cash flow from operations	25 272	63 071
Cash flow from financial activities		
Downpayments of long term group liabilities	-53 113	-44 779
Change in payables/ receivables group companies	4 551	3 806
Received group contribution	25 000	3 619
Paid group contribution	-700	-7 744
Net cash flow from financial activities	-24 262	-45 098
Net change cash and cash equivalents	1 010	17 973
Cash and cash equivalents per 01.01.	26 453	8 480
Cash and cash equivalents per 31.12.	27 463	26 453



Deloitte.

Deloitte AS
Dronning Eufemias gate 14
Postboks 221 Sentrum
NO-0103 Oslo
Norway

Tel: +47 23 27 90 00
www.deloitte.no

Til generalforsamlingen i Viatris AS

UAVHENGIG REVISORS BERETNING

Konklusjon

Vi har revidert Viatris AS' årsregnskap som består av balanse per 31. desember 2021, resultatregnskap og kontantstrømoppstilling for regnskapsåret avsluttet per denne datoen og noter til årsregnskapet, herunder et sammendrag av viktige regnskapsprinsipper.

Etter vår mening

- oppfyller årsregnskapet gjeldende lovkrav, og
- gir årsregnskapet et rettviseende bilde av selskapets finansielle stilling per 31. desember 2021, og av dets resultater og kontantstrømmer for regnskapsåret avsluttet per denne datoen i samsvar med regnskapslovens regler og god regnskapsskikk i Norge.

Grunnlag for konklusjonen

Vi har gjennomført revisjonen i samsvar med de internasjonale revisjonsstandardene International Standards on Auditing (ISA-ene). Våre oppgaver og plikter i henhold til disse standardene er beskrevet nedenfor under *Revisors oppgaver og plikter ved revisjonen av årsregnskapet*. Vi er uavhengige av selskapet slik det kreves i lov, forskrift og International Code of Ethics for Professional Accountants utstedt av the International Ethics Standards Board for Accountants (IESBA-reglene), og vi har overholdt våre øvrige etiske forpliktelser i samsvar med disse kravene. Innhentet revisjonsbevis er etter vår vurdering tilstrekkelig og hensiktsmessig som grunnlag for vår konklusjon.

Øvrig informasjon

Styret og daglig leder (ledelsen) er ansvarlige for informasjonen i årsberetningen. Øvrig informasjon omfatter informasjon i årsrapporten bortsett fra årsregnskapet og den tilhørende revisjonsberetningen. Vår konklusjon om årsregnskapet ovenfor dekker ikke informasjonen i årsberetningen.

I forbindelse med revisjonen av årsregnskapet er det vår oppgave å lese årsberetningen. Formålet er å vurdere hvorvidt det foreligger vesentlig inkonsistens mellom årsberetningen og årsregnskapet og den kunnskap vi har opparbeidet oss under revisjonen av årsregnskapet, eller hvorvidt informasjon i årsberetningen ellers fremstår som vesentlig feil. Vi har plikt til å rapportere dersom årsberetningen fremstår som vesentlig feil. Vi har ingenting å rapportere i så henseende.

Basert på kunnskapen vi har opparbeidet oss i revisjonen, mener vi at årsberetningen

- er konsistent med årsregnskapet og
- inneholder de opplysninger som skal gis i henhold til gjeldende lovkrav.

Ledelsens ansvar for årsregnskapet

Ledelsen er ansvarlig for å utarbeide årsregnskapet og for at det gir et rettviseende bilde i samsvar med regnskapslovens regler og god regnskapsskikk i Norge. Ledelsen er også ansvarlig for slik internkontroll som den finner nødvendig for å kunne utarbeide et årsregnskap som ikke inneholder vesentlig feilinformasjon, verken som følge av misligheter eller utilsiktede feil.

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited ("DTL"), its global network of member firms, and their related entities (collectively, the "Deloitte organization"). DTL (also referred to as "Deloitte Global") and each of its member firms and related entities are legally separate and independent entities, which cannot obligate or bind each other in respect of third parties. DTL and each DTL member firm and related entity is liable only for its own acts and omissions, and not those of each other. DTL does not provide services to clients. Please see www.deloitte.no to learn more.

© Deloitte AS

Registrert i Foretaksregisteret Medlemmer av Den norske Revisorforening
Organisasjonsnummer: 980 211 282

Penneo Dokumentnøkkel: SWUYB-GWGFW-7VTVZ-IKJ1J-Z2P78-GH2QD



Deloitte.

side 2
Uavhengig revisors beretning -
Viatris AS

Ved utarbeidelsen av årsregnskapet må ledelsen ta standpunkt til selskapets evne til fortsatt drift og opplyse om forhold av betydning for fortsatt drift. Forutsetningen om fortsatt drift skal legges til grunn for årsregnskapet så lenge det ikke er sannsynlig at virksomheten vil bli avvirket.

Revisors oppgaver og plikter ved revisjonen av årsregnskapet

Vårt mål er å oppnå betryggende sikkerhet for at årsregnskapet som helhet ikke inneholder vesentlig feilinformasjon, verken som følge av misligheter eller utilsiktede feil, og å avgi en revisjonsberetning som inneholder vår konklusjon. Betryggende sikkerhet er en høy grad av sikkerhet, men ingen garanti for at en revisjon utført i samsvar med ISA-ene, alltid vil avdekke vesentlig feilinformasjon som eksisterer. Feilinformasjon kan oppstå som følge av misligheter eller utilsiktede feil. Feilinformasjon blir vurdert som vesentlig dersom den enkeltvis eller samlet med rimelighet kan forventes å påvirke økonomiske beslutninger som brukerne foretar basert på årsregnskapet.

Som del av en revisjon i samsvar med ISA-ene, utøver vi profesjonelt skjønn og utviser profesjonell skepsis gjennom hele revisjonen. I tillegg:

- identifiserer og vurderer vi risikoen for vesentlig feilinformasjon i regnskapet, enten det skyldes misligheter eller utilsiktede feil. Vi utformer og gjennomfører revisjonshandlinger for å håndtere slike risikoer, og innhenter revisjonsbevis som er tilstrekkelig og hensiktsmessig som grunnlag for vår konklusjon. Risikoen for at vesentlig feilinformasjon som følge av misligheter ikke blir avdekket, er høyere enn for feilinformasjon som skyldes utilsiktede feil, siden misligheter kan innebære samarbeid, forfalskning, bevisste utelatelser, uriktige fremstillinger eller overstyring av internkontroll.
- opparbeider vi oss en forståelse av den interne kontroll som er relevant for revisjonen, for å utforme revisjonshandlinger som er hensiktsmessige etter omstendighetene, men ikke for å gi uttrykk for en mening om effektiviteten av selskapets interne kontroll.
- evaluerer vi om de anvendte regnskapsprinsippene er hensiktsmessige og om regnskapsestimaterne og tilhørende noteopplysninger utarbeidet av ledelsen er rimelige.
- konkluderer vi på hensiktsmessigheten av ledelsens bruk av fortsatt drift-forutsetningen ved avleggelsen av årsregnskapet, basert på innhentede revisjonsbevis, og hvorvidt det foreligger vesentlig usikkerhet knyttet til hendelser eller forhold som kan skape tvil av betydning om selskapets evne til fortsatt drift. Dersom vi konkluderer med at det eksisterer vesentlig usikkerhet, kreves det at vi i revisjonsberetningen henleder oppmerksomheten på tilleggsopplysningene i årsregnskapet, eller, dersom slike tilleggsopplysninger ikke er tilstrekkelige, at vi modifiserer vår konklusjon. Våre konklusjoner er basert på revisjonsbevis innhentet inntil datoen for revisjonsberetningen. Etterfølgende hendelser eller forhold kan imidlertid medføre at selskapet ikke fortsetter driften.
- evaluerer vi den samlede presentasjonen, strukturen og innholdet i årsregnskapet, inkludert tilleggsopplysningene, og hvorvidt årsregnskapet gir uttrykk for de underliggende transaksjonene og hendelsene på en måte som gir et rettviseende bilde.

Vi kommuniserer med styret blant annet om det planlagte omfanget av revisjonen og til hvilken tid revisjonsarbeidet skal utføres. Vi utveksler også informasjon om forhold av betydning som vi har avdekket i løpet av revisjonen, herunder om eventuelle svakheter av betydning i den interne kontrollen.

Oslo, 29. juni 2022
Deloitte AS

Vidar Nilsen
statsautorisert revisor

Penneo Dokumentnøkkel: SWUYB-GWGFW-7VTVZ-IKJTI-Z2P78-GH2QD



PENNEO

Signaturene i dette dokumentet er juridisk bindende. Dokument signert med "Penneo™ - sikker digital signatur".
De signerende parter sin identitet er registrert, og er listet nedenfor.

"Med min signatur bekrefter jeg alle datoer og innholdet i dette dokument."

Vidar Nilsen

Statsautorisert revisor

Serienummer: 9578-5990-4-2892027

IP: 217.173.xxx.xxx

2022-06-29 12:54:54 UTC



Penneo Dokumentnøkkel: SWUYB-GWGFW-7VTVZ-JKTIJ-Z2P78-GH2QD

Dokumentet er signert digitalt, med **Penneo.com**. Alle digitale signatur-data i dokumentet er sikret og validert av den datamaskin-utregnede hash-verdien av det opprinnelige dokument. Dokumentet er låst og tids-stemplet med et sertifikat fra en betrodd tredjepart. All kryptografisk bevis er integrert i denne PDF, for fremtidig validering (hvis nødvendig).

Hvordan bekrefter at dette dokumentet er originalen?

Dokumentet er beskyttet av ett Adobe CDS sertifikat. Når du åpner dokumentet i

Adobe Reader, skal du kunne se at dokumentet er sertifisert av **Penneo e-signature service <penneo@penneo.com>**. Dette garanterer at innholdet i dokumentet ikke har blitt endret.

Det er lett å kontrollere de kryptografiske beviser som er lokalisert inne i dokumentet, med Penneo validator - <https://penneo.com/validate>



Protokoll fra ordinær generalforsamling	Minutes from the annual general meeting
<p style="text-align: center;">Viatrix AS</p> <p>Den 27.juni 2022 ble det avholdt ordinær generalforsamling i Viatrix AS.</p> <p>Tilstede: Luis Birbuet, styreformann Jan Ulrik Stevnsborg, daglig leder og styremedlem Kurt Glud, styremedlem</p> <p>Hele aksjekapitalen var således representert.</p> <p>Til behandling forelå:</p> <ol style="list-style-type: none">1. Valg av møteleder og person til å signere protokollen2. Godkjenning av innkalling og sakliste3. Godkjenning av forslag til årsregnskap, årsberetning beretning, samt anvendelse av resultat4. Godtgjørelse til styremedlemmer5. Godtgjørelse til revisor <p>Sak 1 – Valg av møteleder, samt person til å medundertegne protokollen Generalforsamlingen ble åpnet av styrets leder Luis Birbuet, som også ble valgt til møteleder. Til å undertegne protokollen sammen med møteleder valgte styret Jan Ulrik Stevnsborg.</p> <p>Sak 2 – Godkjenning av innkallingen Det var ingen merknader til saklisten eller innkallingen, og generalforsamlingen ble erklært lovlig satt. Selskapets eneaksjonær samtykket i behandling av sakene på dagsorden, jfr. prinsippet aksjelovens § 5-14 (1).</p> <p>Sak 3 – Godkjenning av styrets forslag til årsregnskap, årsberetning med revisjonsberetning, herunder anvendelse av resultat Styrets forslag til årsregnskap og årsberetning med revisjonsberetning ble gjennomgått.</p>	<p style="text-align: center;">Viatrix AS</p> <p>On June 27, 2022, the annual general meeting of Viatrix AS was held.</p> <p>Present: Luis Birbuet, Chairman of the Board Jan Ulrik Stevnsborg, country manager/ board member Kurt Glud, board member</p> <p>The entire share capital was thus represented.</p> <p>The following matter was dealt with:</p> <ol style="list-style-type: none">1. Election of chair of the meeting and person to co-sign the minutes2. Approval of summons and agenda3. Approval of proposals for annual accounts, annual report with auditor's report, and allocation of results4. Remuneration to board members5. Remuneration to the auditor <p>Item 1 - Election of chair of the meeting, as well as co-sigee of the minutes The general meeting was opened by the chairman of the board, Luis Birbuet, who was also elected chairman of the meeting. The board elected Jan Ulrik Stevnsborg to sign the minutes together with the chairman of the meeting.</p> <p>Item 2 - Approval of the notice There were no comments on the agenda or the notice, and the general meeting was declared lawfully convened. The company's sole shareholder agreed to consider the matters on the agenda, cf. the principle of the Companies Act § 5-14 (1).</p> <p>Item 3 - Approval of the board's proposal for annual accounts, annual report with auditor's report, including allocation of results The board's proposal for annual accounts and annual report with auditor's report were reviewed.</p>



<p>Styret foreslår følgende disponering av årsresultatet i Viatris AS:</p> <table><tr><td>Mottatt konsernbidrag</td><td>-1 244 454</td></tr><tr><td>Avsattkonsernbidrag</td><td>501 650</td></tr><tr><td><u>Overført fra annen egenkapital</u></td><td><u>-3 552 977</u></td></tr><tr><td>Total disponering årsresultat</td><td>-4 295 781</td></tr></table> <p>Sak 4 – Godtgjørelse til styre Etter forslag fra styret ble følgende godtgjørelse foreslått for siste år:</p> <p>Styrets leder: kr. 0 Styremedlemmer: kr. 0</p> <p>Sak 5 – Godtgjørelse til revisor Generalforsamlingen vedtok i samsvar med styrets forslag følgende godtgjørelse til revisor: Revisors honorar dekkes etter regning.</p> <p>Alle beslutninger var enstemmige. Det forelå ikke flere saker til behandling. Protokollen ble godkjent og undertegnet. Møtet ble deretter hevet.</p> <p>Vedlegg:</p> <ol style="list-style-type: none">1. Årsregnskapet for 20212. Revisjonsberetning for 2021	Mottatt konsernbidrag	-1 244 454	Avsattkonsernbidrag	501 650	<u>Overført fra annen egenkapital</u>	<u>-3 552 977</u>	Total disponering årsresultat	-4 295 781	<p>The board proposes the following allocation of the annual result in Viatris AS:</p> <table><tr><td>Received group contribution</td><td>-1 244 454</td></tr><tr><td>Accrued group contribution</td><td>501 650</td></tr><tr><td><u>Transferred from other equity</u></td><td><u>-3 552 977</u></td></tr><tr><td>Total disposition annual result</td><td>-4 295 781</td></tr></table> <p>Item 4 - Remuneration to the board Following a proposal from the board, the following remuneration was proposed for last year:</p> <p>Chairman of the board: kr. 0 Board members: kr. 0</p> <p>Item 5 - Remuneration to the auditor The general meeting approved the following remuneration to the auditor in accordance with the board's proposal: The auditor's fee is covered by invoice.</p> <p>All decisions were unanimous. There were no further matters pending. The minutes were approved and signed. The meeting was then adjourned.</p> <p>Attachments:</p> <ol style="list-style-type: none">1. The annual accounts for 20212. Auditor's report for 2021	Received group contribution	-1 244 454	Accrued group contribution	501 650	<u>Transferred from other equity</u>	<u>-3 552 977</u>	Total disposition annual result	-4 295 781
Mottatt konsernbidrag	-1 244 454																
Avsattkonsernbidrag	501 650																
<u>Overført fra annen egenkapital</u>	<u>-3 552 977</u>																
Total disponering årsresultat	-4 295 781																
Received group contribution	-1 244 454																
Accrued group contribution	501 650																
<u>Transferred from other equity</u>	<u>-3 552 977</u>																
Total disposition annual result	-4 295 781																

Asker, 27.juni 2022

Luis
Birbuet

Digitally signed by Luis Birbuet
DN: cn=Luis Birbuet, o=Viatris,
ou=Viatris Northern & Western Head,
email=luis.birbuet@viatris.com, c=ES
Date: 2022.06.27 14:02:07 +02'00'

Luis Birbuet
Styreleder/ Chairman of the Board

Jan Ulrik
Stevnsborg-
m317141

Digitalt signeret af Jan Ulrik
Stevnsborg-m317141
Dato: 2022.06.29 09:02:58
+02'00'

Jan Ulrik Stevnsborg
Styremedlem/ Board Member



Skatteetaten

Vår dato 14.10.2020	Din/Deres dato 06.10.2020	Saksbehandler Lars Waalorp
800 80 000 Skatteetaten.no	Din/Deres referanse AR392294497	Telefon 32212244
Org.nr 974761076	Vår referanse 2020/5955503	Postadresse Postboks 9200 Grønland 0134 OSLO

MYLAN HEALTHCARE NORGE AS
Hagaløkkveien 26
1383 ASKER

Att. Belinda Hagen

Tillatelse til å utarbeide årsregnskap og årsberetning på engelsk for Mylan Healthcare Norge AS, org.nr. 914 158 877

Vi viser til deres brev av 6. oktober 2020 der det søkes om dispensasjon fra kravet til å utarbeide årsregnskap og årsberetning på norsk for Mylan Healthcare Norge AS.

Skattekontoret gir på bakgrunn av en konkret helhetsvurdering Mylan Healthcare Norge AS dispensasjon fra kravet til å utarbeide årsregnskap og årsberetning på norsk, jf. regnskapsloven § 3-4 tredje ledd. Dispensasjonen gjelder så lenge opplysningene som danner grunnlaget for vedtaket ikke endres vesentlig.

Kopi av dette brevet må sendes til Regnskapsregisteret i Brønnøysund sammen med årsregnskapet. Den regnskapspliktige må selv dokumentere ved dette brev at tillatelse er gitt.

Bakgrunn

Mylan Healthcare Norge AS er eid av et utenlandsk selskap som er en del av et internasjonalt konsern.

Selskapet driver virksomhet innen forretningsområdet legemidler og medisinsk utstyr, og selskapets aktiviteter består i hovedsak av markedsføring, salg og distribusjon av produkter til primært private aktører i helsesektoren i Norge. Engelsk er selskapets arbeidsspråk. Styremedlemmene i selskapet er utenlandske.

Skattekontorets vurdering

Etter regnskapsloven § 3-4 tredje ledd skal "årsregnskapet og årsberetningen [...] være på norsk. Departementet kan ved [...] enkeltvedtak bestemme at årsregnskapet og/eller årsberetningen kan være på et annet språk."

I Ot. prp. nr. 42 (1997-1998) Om lov om årsregnskap mv., er det uttalt følgende om regnskapslovens formål, jf. pkt. 1.1:

"Regjeringen har som siktemål at regnskapsloven skal bidra til informative regnskaper for ulike grupper av regnskapsbrukere. Regnskapsbrukerne er dels investorer og kreditorer som tilfører kapital til foretakene, og dels andre grupper som har interesse av å vite hvordan foretaket drives, f.eks. de ansatte og lokalsamfunnet. Informasjonen til kapitalmarkedet skal gi grunnlag for riktig prising av finansielle objekter. Riktig prisdannelse på aksjer er en forutsetning for at ressursbruken i



samfunnsøkonomien skal bli best mulig. Gode regnskaper vil også gjøre det vanskeligere for markedsdeltakere å ta ut spekulasjonsgevinster med basis i skjevt fordelt informasjon.”

Det fremgår således at et av hovedformålene med regnskapsloven er å bidra til "informative regnskaper for ulike grupper av regnskapsbrukere". Regnskapsbrukere vil omfatte, jf. uttalelsen i proposisjonen, blant andre investorer, kreditorer, ansatte og lokalsamfunnet.

Det er etter skattekontorets vurdering derfor avgjørende ved vurdering av om dispensasjon fra kravet til å utarbeide årsregnskap og/eller årsberetning på norsk kan gis, at det ikke foreligger mulige brukere av regnskapsinformasjon som blir vesentlig berørt negativt ved en eventuell dispensasjon.

Det er særlig hensynet til brukerne av regnskapsinformasjon som skal vurderes ved en dispensasjonssøknad. I denne vurderingen har skattekontoret lagt særlig vekt på at selskapet er direkte eid av et utenlandsk selskap. Videre er det vektlagt at alle sentrale aktører og samarbeidspartnere i bransjen behersker og benytter engelsk.

Vennligst oppgi vår referanse ved henvendelse i saken.

Med hilsen

Lars Waalorp
seniorrådgiver
Brukerdialog, brukerkontakt
Skatteetaten

Dokumentet er elektronisk godkjent og har derfor ikke håndskrevne signaturer.